Progyny, Inc. (PGNY)
NASDAQ: PGNY · IEX Real-Time Price · USD
31.72
-0.35 (-1.09%)
At close: May 3, 2024, 4:00 PM
32.00
+0.28 (0.88%)
After-hours: May 3, 2024, 6:44 PM EDT

Progyny Revenue

In the year 2023, Progyny had annual revenue of $1.09B with 38.34% growth. Revenue in the quarter ending December 31, 2023 was $269.94M with 25.95% year-over-year growth.

Revenue (ttm)
$1.09B
Revenue Growth
+38.34%
P/S Ratio
2.81
Revenue / Employee
$1,923,318
Employees
566
Market Cap
3.06B USD

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 20231.09B301.69M38.34%
Dec 31, 2022786.91M286.29M57.19%
Dec 31, 2021500.62M155.76M45.17%
Dec 31, 2020344.86M115.18M50.15%
Dec 31, 2019229.68M124.28M117.92%
Dec 31, 2018105.40M56.82M116.94%
Dec 31, 201748.58M--
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Surgery Partners 2.74B
Amedisys 2.25B
Evolent Health 1.96B
Sotera Health Company 1.05B
10x Genomics 625.45M
Amicus Therapeutics 399.36M
Immunocore Holdings 249.43M
Arrowhead Pharmaceuticals 181.74M
Revenue Rankings